Combined Use of Meropenem, Linezolid, and Quinolones for Non-Drug-Resistant Tuberculosis in Critically Ill Patients and Other Settings: A Descriptive Series
Abstract
Meropenem, linezolid, and quinolones are alternatives for managing tuberculosis (TB) in cases of drug-related adverse reactions, critical ill patients, organ failure, or inability to use the oral route.
AIM
To report the experience with the combined use of these compounds in cases of TB not associated with drug-resistant tuberculosis.
METHODS
Observational study of patients hospitalized for TB between 2020 and 2024 treated with these compounds at a regional hospital in Chile.
RESULTS
Ten male patients (median age 43.5 years), were treated with this combination either by adverse drug reactions (4 cases), hepatitis- liver failure (3 cases), respiratory failure, suspected gastrointestinal bleeding or a critical condition (1 each one). Combination therapy was used during the initial intensive (9 cases) or continuation phase (1 case). Median meropenem doses was 3 g/day for 2 weeks, 1,200 mg/day of linezolid for 2 weeks, and 750 mg/day of levofloxacin in 7 cases for 3 weeks or moxifloxacin (400 mg/day). Five patients were admitted to critical intensive care units. In 2 cases with a prolonged alternative treatment (≥ 4 weeks), M. tuberculosis culture became negative. Anemia secondary to linezolid was observed in 6 cases, one requiring transfusion. Linezolid and meropenem therapeutic drug monitoring was applied in one case. WHO treatment outcome was classified as treatment success in 4 cases, dead in 4 (3 treated on a premortem basis), abandonment in one, and one still under…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.